Abstract

CURRENT STATUS OF PEPTIDE-DRUG CONJUGATE FOR LUNG NEUROENDOCRINE TUMORS THERAPY: A PROSPECTIVE VIEWPOINT

Janisa Kabir, Hamza Boucetta, Md. Fahim Shahriar and Zhenghong Wu*

ABSTRACT

Neuroendocrine tumors (NET) form in the body's neuroendocrine system and are considered malignant; it takes years for most NETs to evolve, but not all. NETs are predominantly located in the lungs and the gastrointestinal tract; NETs in the lungs are carcinoid tumors. Treating these tumors is challenging, and therapeutic strategies have become priorities for researchers and clinicians. A neuroendocrine lung tumor is one such tumor that is very difficult to treat. To manage hormonal disorders caused by neuroendocrine tumors, somatostatin analogs are the gold standard. New data suggests that somatostatin analogs can be antiproliferative treatments for neuroendocrine tumors. Despite their apparent clinical interchangeability, comparative noninferiority studies between octreotide and lanreotide have not been conducted. Thus, it is where we look at different drug conjugates which act on the tumor. Radioligand, for example, is a promising model for Peptide Somatostatin receptors, typically more expressed on the surface of metastatic lung NETs.Consequently, a radioligand-based drug-peptide delivery is a particular target delivery method. Another type of drug conjugate is the novel technology named Peptide-drug conjugate (PDC) has made slow and steady progress in this treatment. PDC has the advantage of covalently altering a ligand peptide, which can target the specific cell surface receptors or biomarkers at the tumor site, exert a long-lasting function, and extend the effect of time, resulting in an overall desirable pharmacokinetic profile as a means of delivering anticancer drugs. Therefore, this review will summarize the recent technologies and anticancer agents that PDC used for the therapeutic efficiency and the intracellular uptake efficiency of active ingredients and receptors expressed on LU-NETs cells.

Keywords: Lung cancer; Lung neuroendocrine tumors; Peptide-based delivery; Peptide drug conjugate.